Research
Hormonal
Dim Light Melatonin Onset (DLMO) is a more stable and accurate marker of circadian phase than Core Body Temperature (CBT) because it is less susceptible to masking effects.
For accurate diagnosis of circadian disorders, measuring the Dim Light Melatonin Onset (DLMO) is superior to using Core Body Temperature. DLMO is less affected by daily activities and provides a more stable marker of your internal clock's phase, facilitating more precise treatment planning.
WeakSupportsHIGH confidence
These findings provide strong support for the melatonin profile as the most stable, and therefore presumably the most accurate, currently available marker for circadian phase.
Why this rating
Supported by multiple studies cited (Shanahan, Klerman, Benloucif) showing high correlation and stability.
Source
Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders
Robert L. Sack et al. · SLEEP · 2007
DOI 10.1093/sleep/30.11.1460
narrative_reviewCited 643×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Blue wavelength light is the most efficient stimulus for shifting the circadian system and suppressing melatonin due to its sensitivity in non-rod, non-cone photoreceptors.Limited
- Circadian misalignment between endogenous rhythms and exogenous sleep schedules causes Shift Work Disorder (SWD) and Jet Lag Disorder (JLD), characterized by sleep disturbance and impairment.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →